0000000000877969

AUTHOR

Job J.m.h. Van Bragt

showing 2 related works from this author

The influence of smoking status on exhaled breath profiles in asthma and COPD patients

2021

Breath analysis using eNose technology can be used to discriminate between asthma and COPD patients, but it remains unclear whether results are influenced by smoking status. We aim to study whether eNose can discriminate between ever- vs. never-smokers and smoking &lt

MaleCopd patientsPharmaceutical ScienceeNoseAnalytical ChemistryPulmonary Disease Chronic Obstructive0302 clinical medicineDrug DiscoveryElectronic Nose0303 health sciencesCOPDConfoundingfood and beveragesMiddle AgedBreath Testsexhaled breathChemistry (miscellaneous)ExhalationMolecular MedicineSmoking statusFemaleAdultmedicine.medical_specialtySmoking habitPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlesmokinglcsh:QD241-44103 medical and health scienceslcsh:Organic chemistryInternal medicinemedicineHumansCOPDPhysical and Theoretical Chemistry030304 developmental biologyAsthmaVolatile Organic Compoundsbusiness.industryfungiOrganic Chemistryasthmamedicine.diseaserespiratory tract diseasesCross-Sectional Studies030228 respiratory systemBreath gas analysisROC CurveAsthma COPD eNose Exhaled breath SmokingCase-Control Studiesbusiness
researchProduct

Treating severe asthma:Targeting the IL‐5 pathway

2021

Abstract Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)‐4, IL‐5 and IL‐13). Monoclonal antibodies that target the eosinophilic inflammatory pathways (IL‐5R and IL‐5), namely mepolizumab, reslizumab, and benralizumab, are effective and safe for severe eosinophilic asthma. Eosinophils threshold represents the most indicative biomarker for response to treatment with all three monoclonal antibodies. Improvement in asthma symptoms scores, lung function, the number of exacerbations, history of late‐o…

0301 basic medicineImmunologyReview ArticleDisease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineReslizumabEosinophilicHumansImmunology and AllergyMedicineInvited ReviewsAnti-Asthmatic AgentsInterleukin 5Asthmabusiness.industryAnti-Asthmatic Agents Asthma Eosinophils Interleukin-5medicine.diseaseBenralizumabAsthmaEosinophils030104 developmental biology030228 respiratory systemchemistryImmunologyBiomarker (medicine)Interleukin-5businessMepolizumabmedicine.drug
researchProduct